The negative impact of brain disorders is expected to worsen over the coming years as the COVID-19 pandemic served as an unprecedented global stress test. Furthermore, because we are increasingly a ‘Brain Economy’, we need to ensure people are mentally healthy, so our societies continue to be productive. Neuroscience investments are fundamental to achieving such long-term economic resilience.
Figure 1— Historical number of M&A deals in the neuroscience space
The GNM had a value of $612 billion in 2022, with an outstanding 73 percent derived from non-drug therapies. The GNM is forecast to grow at a relatively low rate in the coming years, featuring a compound annual growth rate (CAGR) of 4.2 percent until 2026 with a valuation of $721 billion.
Figure 2—Overview of the global neuroscience market share across geographical regions by segment, 2022
The analysis reflects Deloitte’s current view on potential investment opportunities in neuroscience by presenting a selection of segments, their forecasted returns, and estimated growth rates, based also on regional differentiators and local developments. The global neuroscience market offers attractive return potential. Investment bodies may infer future growth, and therefore projected return on investment based on current revenue levels across segments of the global neuroscience market. Moreover, private equity, venture capital and corporate M&A organisations may adjust their investment strategy according to the target region.